HKMPF (Hikma Pharmaceuticals) Accounts Payable: $400 Mil (As of Dec. 2025)


HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $21.26
GF Value $28.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Accounts Payable?

Hikma Pharmaceuticals HKMPF -2.01% 82 Accounts Payable is $400 Mil as of Dec. 2025. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2025 was $400 Mil.

Hikma Pharmaceuticals's quarterly Accounts Payable increased from Dec. 2024 ($358 Mil) to Jun. 2025 ($611 Mil) but then declined from Jun. 2025 ($611 Mil) to Dec. 2025 ($400 Mil).

Hikma Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 ($309 Mil) to Dec. 2024 ($358 Mil) and increased from Dec. 2024 ($358 Mil) to Dec. 2025 ($400 Mil).

Hikma Pharmaceuticals Accounts Payable Related Terms

Hikma Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Accounts Payable Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 262.00 291.00 309.00 358.00 400.00

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.00 541.00 358.00 611.00 400.00
HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $400 Mil mean?
Hikma Pharmaceuticals (HKMPF) has a Accounts Payable of $400 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Accounts Payable too high?
Hikma Pharmaceuticals' current Accounts Payable is $400 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Accounts Payable compare to ZTS and UTHR?
Hikma Pharmaceuticals' Accounts Payable of $400 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Accounts Payable is $400 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.52, compared to a current price of $21.26 — trading 25.5% below its estimated fair value. The current Accounts Payable is $400 Mil. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Accounts Payable is $400 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.52. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Accounts Payable: $400 Mil
  • GF Value™: $28.52 vs. price of $21.26 (25.5% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.26
Price
$28.52
GF Value